|
注册号: Registration number: |
ChiCTR-ROC-17012814 |
|
最近更新日期: Date of Last Refreshed on: |
2017-09-26 22:09:22 |
|
注册时间: Date of Registration: |
2017-09-26 00:00:00 |
|
注册号状态: |
补注册 |
|
Registration Status: |
Retrospective registration |
|
注册题目: |
急性心肌梗死患者经皮冠状动脉介入治疗后无复流冠脉内压力测定 |
|
Public title: |
Intracoronary pressure gradient measurement applied to the acute myocardial infraction patients with no-reflow phenomenon after primary percutaneous coronary intervention |
|
注册题目简写: |
|
|
English Acronym: |
|
|
研究课题的正式科学名称: |
急性心肌梗死患者急诊经皮冠状动脉介入治疗术后无复流前后冠脉内压力测定 |
|
Scientific title: |
Intracoronary pressure gradient measurement applied to the acute myocardial infraction patients with no-reflow phenomenon before and after primary percutaneous coronary intervention |
|
研究课题代号(代码): Study subject ID: |
|
|
在二级注册机构或其它机构的注册号: The registration number of the Partner Registry or other register: |
|
申请注册联系人: |
刘远莹 |
研究负责人: |
高明东 |
|
Applicant: |
Yuanying Liu |
Study leader: |
Mingdong Gao |
|
申请注册联系人电话: Applicant telephone: |
+86 13702194921 |
研究负责人电话:
Study leader's |
+86 15320083229 |
|
申请注册联系人传真 : Applicant Fax: |
研究负责人传真: Study leader's fax: |
||
|
申请注册联系人电子邮件: Applicant E-mail: |
yuanyingliu1987@163.com |
研究负责人电子邮件: Study leader's E-mail: |
gaomd000@sinia.com |
|
申请单位网址(自愿提供): Applicant website(voluntary supply): |
研究负责人网址(自愿提供): Study leader's website(voluntary supply): |
||
|
申请注册联系人通讯地址: |
天津市津南区吉兆路261号天津市胸科医院心内科 |
研究负责人通讯地址: |
天津市津南区吉兆路261号天津市胸科医院心内科 |
|
Applicant address: |
261 Jizhao Road, TianJin, China |
Study leader's address: |
261 Jizhao Road, TianJin, China |
|
申请注册联系人邮政编码: Applicant postcode: |
研究负责人邮政编码: Study leader's postcode: |
||
|
申请人所在单位: |
天津市胸科医院 |
||
|
Applicant's institution: |
Tianjin Chest Hospital |
||
|
研究负责人所在单位: |
天津市胸科医院 |
||
|
Affiliation of the Leader: |
Department of Cardiology, Tianjin Chest Hospital |
||
|
是否获伦理委员会批准: |
是 |
||
|
Approved by ethic committee: |
Yes |
||
|
伦理委员会批件文号: Approved No. of ethic committee: |
2017LW-002 |
伦理委员会批件附件: Approved file of Ethical Committee: |
查看附件View |
|
批准本研究的伦理委员会名称: |
天津市胸科医院伦理委员会 |
||
|
Name of the ethic committee: |
Tianjin chest hospital ethics committee |
||
|
伦理委员会批准日期: Date of approved by ethic committee: |
1990-01-01 00:00:00 | ||
|
伦理委员会联系人: |
|
||
|
Contact Name of the ethic committee: |
|
||
|
伦理委员会联系地址: |
|
||
|
Contact Address of the ethic committee: |
|
||
|
伦理委员会联系人电话: Contact phone of the ethic committee: |
伦理委员会联系人邮箱: Contact email of the ethic committee: |
||
|
研究实施负责(组长)单位: |
天津市胸科医院心内科 |
||||||||||||||||||||||
|
Primary sponsor: |
Department of Cardiology, Tianjin Chest Hospital |
||||||||||||||||||||||
|
研究实施负责(组长)单位地址: |
天津市津南区吉兆路261号天津市胸科医院心内科 |
||||||||||||||||||||||
|
Primary sponsor's address: |
261 Jizhao Road, TianJin, China |
||||||||||||||||||||||
|
试验主办单位(项目批准或申办者): Secondary sponsor: |
|
||||||||||||||||||||||
|
经费或物资来源: |
无资金资助 |
||||||||||||||||||||||
|
Source(s) of funding: |
no funding |
||||||||||||||||||||||
|
研究疾病: |
急性心肌梗死 |
||||||||||||||||||||||
|
Target disease: |
AMI |
||||||||||||||||||||||
|
研究疾病代码: |
|
||||||||||||||||||||||
|
Target disease code: |
|
||||||||||||||||||||||
|
研究类型: |
病因学/相关因素研究 |
||||||||||||||||||||||
|
Study type: |
Cause/Relative factors study |
||||||||||||||||||||||
|
研究所处阶段: |
其它 | ||||||||||||||||||||||
|
Study phase: |
N/A |
||||||||||||||||||||||
|
研究设计: |
单臂 |
||||||||||||||||||||||
|
Study design: |
Single arm |
||||||||||||||||||||||
|
研究目的: |
急性心肌梗死患者急诊PCI术后出现无复流现象,无复流冠脉远端应用扩血管药物后血流恢复的机制尚不明确。我们在应用冠脉内扩血管药物前后测量冠脉内压力梯度,有助于我们理解在急性心肌梗死患者急诊PCI术后无复流是远端应用扩血管药物的血流动力学机制。 |
||||||||||||||||||||||
|
Objectives of Study: |
Our results provide new insights into the intracoronary pressure gradient measurement contributing to understand the hemodynamic mechanism of distal vasodilators administration effective to the AMI patients with no-reflow phenomenon after primary PCI. |
||||||||||||||||||||||
|
药物成份或治疗方案详述: |
|
||||||||||||||||||||||
|
Description for medicine or protocol of treatment in detail: |
|
||||||||||||||||||||||
|
纳入标准: |
|||||||||||||||||||||||
|
Inclusion criteria |
|||||||||||||||||||||||
|
排除标准: |
1、严重低血压,中重度充血性心力衰竭,血流动力学不稳定;2、血栓性病变;3;房早,室早,房颤等心律失常;4、冠脉开口病变;5、冠脉严重血管迂曲,抽吸导管送入或拉出时导致压力变形或图形不连续;6、低压力模式,压力图形不理想;7、测定血管直径小于抽吸导管外径。 |
||||||||||||||||||||||
|
Exclusion criteria: |
significant hypotension, arrhythmia, severe or moderate congestive heart failure, coronary ostial lesions, significant vascular tortuosity, poor Pressure pattern , unsuccessful angioplasty, incomplete pressure monitor study . |
||||||||||||||||||||||
|
研究实施时间: Study execute time: |
从 From 2015-10-01 00:00:00至 To 2018-10-01 00:00:00 |
征募观察对象时间: Recruiting time: |
从 From 2015-10-01 00:00:00 至 To 2018-10-01 00:00:00 |
|
干预措施: Interventions: |
|
|
研究实施地点: Countries of recruitment and research settings: |
|
||||||||||||||||||||||||||||
|
测量指标: Outcomes: |
|
|
采集人体标本:
Collecting sample(s)
|
|
|
征募研究对象情况: Recruiting status: |
正在进行 Recruiting |
年龄范围: Participant age: |
|
||||||
|
性别: |
男女均可 |
Gender: |
Both |
||||||
|
随机方法(请说明由何人用什么方法产生随机序列): |
由高明东操作,计算机产生随机数进行随机化 |
||||||||
|
Randomization Procedure (please state who generates the random number sequence and by what method): |
Performed by Gao Mingdong,computer generated random number for randomization |
||||||||
|
是否公开试验完成后的统计结果: Calculated Results after the Study Completed public access: |
不公开/Private |
|
盲法: |
|
|
Blinding: |
|
是否共享原始数据: IPD sharing |
是Yes |
|
共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址): |
2019年3月1日通过ResMan |
|
The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url): |
IPD will be public accessable via ResMan after 2019-3-1 |
|
数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC: |
数据采集,病例记录表包括:病人的基本信息,术中压力测定曲线表、血液相关结果测定 |
|
Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture: |
Data collection, case records include: the basic information of the patients, intraoperative determination of pressure curve table, blood related results |
|
数据与安全监察委员会: Data and Safety Monitoring Committee: |